• Share
  • Email
  • Embed
  • Like
  • Private Content
Woerwag RD presentation
 

Woerwag RD presentation

on

  • 1,161 views

Woerwag R & D Company presentation

Woerwag R & D Company presentation

Statistics

Views

Total Views
1,161
Views on SlideShare
1,161
Embed Views
0

Actions

Likes
0
Downloads
3
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Woerwag RD presentation Woerwag RD presentation Presentation Transcript

    • WÖRWAG R&D GmbH - Company profile for products to licenceoutWörwag Research and Development GmbHA subsidiary of the Wörwag Pharma Group dedicated to the development of: ● Generic ● OTC ● NCE products and ● Medical devicesaccording to European guidelinesMission ● Provide excellent products right in time for launch with maximum therapeutic benefit for our patientsMarch 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
    • WÖRWAG R&D GmbH - Company profile for products to licenceoutWörwag Research and Development GmbHBusiness model ● Licensing-out developments done by Wörwag R&D in Europe and Worldwide on a national, European or worldwide basis.Please find Wörwag R&D’s current development list and compiled / approveddossiers on the following pages or on our homepage:www.woerwag-rd.comMarch 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
    • WÖRWAG R&D GmbH - Company profile for products to licence out(I)Readily Compiled Dossiers (I):Following dossiers are readily compiled and have received German and selectedEuropean Marketing Authorisations. They are ready for submission in othermarkets: ● Clopidogrel film coated tablets (75 mg); Original: Plavix, Iscover ● Candesartan tablets (2 | 4 | 8 | 16 | 32 mg), Original: Atacand ● Donepezil film coated tablets (5 | 10 mg), Original: Aricept ● Levetiracetam film coated tablets (250 | 500 | 750 | 1000 mg), Original: Keppra ● Pioglitazon tablets (15 | 30 | 45 mg), Original: Actos of German origin (Bulk and Packaging)March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
    • WÖRWAG R&D GmbH - Company profile for products to licence out(II)Readily Compiled Dossiers (II): ● Valsartan tablets (40 | 80 | 160 | 320 mg), Original: Diovan of German origin (Bulk and Packaging) ● Losartan film coated tablets (12,5 | 25 | 50 | 100 mg); Original: Lorzaar ● Losartan-HCT film coated tablets (50/12,5 | 100/12,5 | 100/25 mg); Original: Lorzaar PlusMarch 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
    • WÖRWAG R&D GmbH - Company profile for products to licence out(III)Readily Compiled Dossiers (III): ● Torasemid tablets (2,5 | 5 | 10 | 20 | 200 mg); Original: Torem, Unat ● Xipamid tablets (10 | 20 | 40 mg); Original: Aquaphor ● Enalapril-HCT tablets (20/12,5 mg); Original: Benalapril Plus ● HCT tablets (12,5 | 25 mg); Original: Esidrix ● Milk Thistle Dry Extract, film coated tablets, corresponding to 150 mg Silymarin (UV) ● Milk Thistle Dry Extract, capsules, corresponding to 86,5 mg Silymarin (HPLC) ● Capsicum Cream (0,05 % Capsaicin), OTC product indicated for pain relief due to chronic diabetic neuropathy All products above are of German origin (Bulk and Packaging)March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
    • WÖRWAG R&D GmbH - Company profile for products to licence out(IV)Ongoing developments ● Candesartan-HCT tablets (8/12,5 | 16/12,5 | 32/12,5 | 32/25 mg), Dossier ready until Q III-2011, DCP in Q IV-2011; Original: Atacand Plus ● Galantamine XR capsules (8 | 16 | 24 mg), Dossier ready,DCP ongoing; Original: Reminyl ● Duloxetin gastro-resistant capsules (30 | 60 mg),Dossier ready in 2012, Data protection period until Aug. 2014; Original: Cymbalta of German origin (Bulk and Packaging)Please find more details on our homepage at:www.woerwag-rd.comMarch 2011 I Wörwag R&D I Business Development www.woerwag-rd.com
    • WÖRWAG R&D GmbH - Company profile for products to licenceout Contact Wörwag R & D GmbH Calwer Str. 7 D-71034 Böblingen Germany Dr. Wolfgang Bäurle Head Business Development Tel.: +49 7031-6204-794 Fax: +49 7031-6204-72 E-mail: Wolfgang.Baeurle@woerwagpharma.com Internet: www.woerwag-rd.comMarch 2011 I Wörwag R&D I Business Development I Dr. Wolfgang Bäurle www.woerwag-rd.com